References from scientific journals

How Taxol/paclitaxel kills cancer cells.

Weaver BA. Weaver BA. Mol Biol Cell. 2014 Sep 15;25(18):2677-81. doi: 10.1091/mbc.E14-04-0916. Mol Biol Cell. 2014. PMID: 25213191 Free PMC article.

Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. ...It is hoped that this insight can now be used to develop a b …
Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatm …

Progress in research on paclitaxel and tumor immunotherapy.

Zhu L, Chen L. Zhu L, et al. Cell Mol Biol Lett. 2019 Jun 13;24:40. doi: 10.1186/s11658-019-0164-y. eCollection 2019. Cell Mol Biol Lett. 2019. PMID: 31223315 Free PMC article. Review.

Paclitaxel is a well-known anticancer agent with a unique mechanism of action. ...Recently, paclitaxel has been found to play a large role in tumor immunity, and it has a great potential for use in many cancer treatments....
Paclitaxel is a well-known anticancer agent with a unique mechanism of action. ...Recently, paclitaxel has been found to play …

Paclitaxel.

Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT. Alqahtani FY, et al. Profiles Drug Subst Excip Relat Methodol. 2019;44:205-238. doi: 10.1016/bs.podrm.2018.11.001. Epub 2019 Apr 22. Profiles Drug Subst Excip Relat Methodol. 2019. PMID: 31029218

Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. ...It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of …
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of …

Albumin-bound paclitaxel in solid tumors: clinical development and future directions.

Kundranda MN, Niu J. Kundranda MN, et al. Drug Des Devel Ther. 2015 Jul 24;9:3767-77. doi: 10.2147/DDDT.S88023. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26244011 Free PMC article. Review.

Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentia …
Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more …

Paclitaxel: a review of adverse toxicities and novel delivery strategies.

Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Marupudi NI, et al. Expert Opin Drug Saf. 2007 Sep;6(5):609-21. doi: 10.1517/14740338.6.5.609. Expert Opin Drug Saf. 2007. PMID: 17877447 Review.

Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. ...However, significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based t …
Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. …

The battle of "nano" paclitaxel.

Sofias AM, Dunne M, Storm G, Allen C. Sofias AM, et al. Adv Drug Deliv Rev. 2017 Dec 1;122:20-30. doi: 10.1016/j.addr.2017.02.003. Epub 2017 Feb 28. Adv Drug Deliv Rev. 2017. PMID: 28257998 Review.

In 2005, the introduction of the albumin-based formulation of PTX, known as Abraxane, ended Taxol's monopoly of the PTX market. Abraxane's ability to push the Taxol innovator and generic formulations aside attracted fierce competition amongst competitors worldwide t …
In 2005, the introduction of the albumin-based formulation of PTX, known as Abraxane, ended Taxol's monopoly of the PTX market. Abrax …

Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.

Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H. Adrianzen Herrera D, et al. Expert Opin Pharmacother. 2019 Jan;20(1):95-102. doi: 10.1080/14656566.2018.1546290. Epub 2018 Nov 15. Expert Opin Pharmacother. 2019. PMID: 30439289 Review.

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor, has demonstrated clinical efficacy in the treatment of advanced non-small cell lung cancer (NSCLC) either as monotherapy or in combination. Nab-paclitaxel was developed to reduce …
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor, has demonstrated clinical efficacy in the tre …

Taxotere.

Renick-Ettinger A. Renick-Ettinger A. J Pediatr Oncol Nurs. 1996 Jan;13(1):43-5. doi: 10.1177/104345429601300109. J Pediatr Oncol Nurs. 1996. PMID: 8904466 Review. No abstract available.


Taxanes.

Fojo A. Fojo A. Cancer Chemother Biol Response Modif. 1996;16:57-67. Cancer Chemother Biol Response Modif. 1996. PMID: 8639402 Review. No abstract available.


Paclitaxel.

Hoyer KA. Hoyer KA. Clin J Oncol Nurs. 2000 Jan-Feb;4(1):51-2. Clin J Oncol Nurs. 2000. PMID: 10865588 Review. No abstract available.